Unknown EARLY_PHASE1 INTERVENTIONAL 1-arm NCT04049864

DNA Vaccination Against Neuroblastoma

Pilot Clinical Study of DNA Vaccination Against Neuroblastoma

Sponsor: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

Interventions DNA vaccine Lenalidomide Salmonella oral vaccine

Updated 7 times since 2019 Last updated: Mar 1, 2022 Started: Jan 9, 2019 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04049864, this EARLY_PHASE1 trial focuses on Relapsed Neuroblastoma and remains ongoing. Sponsored by Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, it has been updated 7 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown EARLY_PHASE1

Status: Unknown Status → Unknown
Apr 2024 — Jul 2024 [monthly]

Unknown Status EARLY_PHASE1

Status: Recruiting → Unknown Status
Apr 2022 — Apr 2024 [monthly]

Recruiting EARLY_PHASE1

Status: Unknown Status → Recruiting
Jan 2022 — Apr 2022 [monthly]

Unknown Status EARLY_PHASE1

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Jan 2022 [monthly]

Recruiting EARLY_PHASE1
Sep 2019 — Jan 2021 [monthly]

Recruiting EARLY_PHASE1

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

Data source: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minsk, Belarus